Back to Journals » OncoTargets and Therapy » Volume 6
Immunomodulatory effects of the botanical compound LCS101: implications for cancer treatment
Authors Rachmut IH, Samuels N , Melnick SJ, Ramachandran C, Sharabi Y, Pavlovsky A, Maimon Y, Shoham J
Received 24 December 2012
Accepted for publication 4 February 2013
Published 24 April 2013 Volume 2013:6 Pages 437—445
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Itzchak H Rachmut,1 Noah Samuels,2,* Steven J Melnick,3 Cheppail Ramachandran,4 Yedida Sharabi,1 Anya Pavlovsky,1 Yair Maimon,5 Jacob Shoham1
1The Gonda-Goldschmied Center, Bar-Ilan University, Ramat-Gan, Israel; 2Center for Integrative Complementary Medicine, Shaare Zedek Medical Center, Jerusalem, Israel; 3Department of Pathology, 4Research Institute, Miami Children's Hospital, Miami, FL, USA; 5Refuot Integrative Medical Center, Tel Aviv, Israel
*Joint first author
Objective: To examine the effects of LSC101, a botanical compound, on adaptive and innate immunity.
Materials and methods: LCS101 preparations were tested for batch-to-batch consistency using high-performance liquid chromatography. T-cell activation was quantified in murine spleen cells using 3H-thymidine incorporation, and cytokine production analyzed with enzyme-linked immunosorbent assay. Natural killer cell activity was tested on human blood cells using flow cytometry, and cytotoxicity measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and apoptosis using a FACSCalibur. Effects on interferon-γ production in fluorouracil/doxorubicin-treated mice were tested with enzyme-linked immunosorbent assay.
Results: High-performance liquid chromatography analysis demonstrated batch-to-batch consistency. T-cell proliferation was increased, and a dose-dependent activation of natural killer cells and macrophage tumor necrosis factor-α secretion were observed with LCS101 treatment. Interferon-γ levels, reduced following fluorouracil treatment, were corrected in treated animals. No toxicity or compromised treatment outcomes were associated with LCS101 exposure.
Conclusions: LCS101 demonstrated significant effects on a number of immune processes. Further research is needed in order to understand the molecular immunomodulatory pathways affected by this compound, as well as clinical implications for treatment.
Keywords: botanical compound, immunomodulation, T-cell immunity, NK cells, interferon-gamma, TNF-alpha
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.